yanzheng

Comprehensive Hyperuricemia Model

分类：

Model Introduction

Hyperuricemia (HUA) is the biochemical foundation and core pathological prerequisite for the occurrence of gouty arthritis. Since experimental animals possess uricase, which metabolizes uric acid into allantoin, constructing this model requires artificial intervention to inhibit uric acid metabolism or increase uric acid sources. Among the various protocols provided in the references, the comprehensive model using Potassium Oxonate combined with uric acid precursors (such as hypoxanthine, adenine, etc.) is the ideal surrogate for studying gout-related metabolic disorders and drug interventions due to its high stability, long experimental cycle, and minimal damage to the animal’s body.

Research Applications

  1. Research on the pathogenesis of hyperuricemia and gout.
  2. Screening and efficacy evaluation of drugs for the prevention and treatment of hyperuricemia and gout.
  3. Research on complications such as renal injury caused by abnormal uric acid metabolism.

Key Points of Experimental Design

  • Species: Primarily rodents; rats are the main experimental animals, while mice can be used for acute models.
  • Method: Combined multi-factor administration.
  • Key Steps:
    1. Drug Formulation: Combined use of Potassium Oxonate (0.25g/kg), Yeast (30g/kg), Hypoxanthine (1g/kg), Adenine (0.1g/kg), and Ethambutol (0.25g/kg).
    2. Administration: Continuous oral gavage for 14 days.
    3. Principle: Potassium oxonate inhibits uricase activity (inhibits metabolism), while yeast and hypoxanthine increase uric acid sources, and ethambutol inhibits uric acid excretion, inducing significantly elevated blood uric acid levels through multiple pathways.
  • Characteristics: Significant effect (uric acid levels can increase by approximately 108%) and high stability.

Key Monitoring Indicators

  1. Biochemical Indicators: Serum Uric Acid (UA) levels (significantly increased), Creatinine (Cr), Blood Urea Nitrogen (BUN).
  2. Physical Signs: Body weight changes (typically a decrease), activity levels (decreased), and coat condition (e.g., alopecia).
  3. Histopathology: Gross and microscopic observation of the kidneys (e.g., increased glomerular volume, vacuolar degeneration, tubular protein exudation, and other signs of renal injury).
  4. Other Indicators: No records available based on current data.

相关产品